[
    {
        "No.": "1",
        "Ticker": "TPHS",
        "Company": "Trinity Place Holdings Inc",
        "Sector": "Real Estate",
        "Industry": "Real Estate - Development",
        "Country": "USA",
        "Market Cap": "14.41M",
        "Price": "0.22",
        "Change": "85.34%",
        "Volume": "336,824,980",
        "Sentiment Scores": []
    },
    {
        "No.": "2",
        "Ticker": "PRST",
        "Company": "Presto Automation Inc",
        "Sector": "Technology",
        "Industry": "Software - Application",
        "Country": "USA",
        "Market Cap": "14.13M",
        "Price": "0.12",
        "Change": "59.42%",
        "Volume": "219,661,259",
        "Sentiment Scores": []
    },
    {
        "No.": "3",
        "Ticker": "CLEU",
        "Company": "China Liberal Education Holdings Ltd",
        "Sector": "Consumer Defensive",
        "Industry": "Education & Training Services",
        "Country": "China",
        "Market Cap": "10.42M",
        "Price": "3.11",
        "Change": "53.96%",
        "Volume": "13,887,889",
        "Sentiment Scores": []
    },
    {
        "No.": "4",
        "Ticker": "AONC",
        "Company": "American Oncology Network Inc",
        "Sector": "Healthcare",
        "Industry": "Medical Care Facilities",
        "Country": "USA",
        "Market Cap": "21.39M",
        "Price": "2.23",
        "Change": "31.18%",
        "Volume": "2,297,380",
        "Sentiment Scores": []
    },
    {
        "No.": "5",
        "Ticker": "GDXD",
        "Company": "MicroSectors Gold Miners -3X Inverse Leveraged ETNs",
        "Sector": "Financial",
        "Industry": "Exchange Traded Fund",
        "Country": "USA",
        "Market Cap": "-",
        "Price": "24.26",
        "Change": "20.82%",
        "Volume": "937,285",
        "Sentiment Scores": []
    },
    {
        "No.": "6",
        "Ticker": "GERN",
        "Company": "Geron Corp.",
        "Sector": "Healthcare",
        "Industry": "Biotechnology",
        "Country": "USA",
        "Market Cap": "2.78B",
        "Price": "4.68",
        "Change": "20.43%",
        "Volume": "76,731,607",
        "Sentiment Scores": [
            {
                "headline": "Geron stock pops on FDA approval for blood cancer drug",
                "headline_score": 0.8633092641830444,
                "headline_label": "positive",
                "article_text": "Geron stock pops on FDA approval for blood cancer drug\nJulie Hyman and Jared Blikre\nFri, Jun 7, 2024, 2:51 PM\nIn This Article:\nGERN\nShares of Geron (GERN) are trading higher Friday, propelled by the recent Food & Drug Administration (FDA) approval of the company's blood disorder drug, Rytelo. The treatment is for adults with low- to intermediate-1 risk of myelodysplastic syndromes, a type of cancer.\nFor more expert insight and the latest market action, click here to watch this full episode of Market Dominat",
                "text_score": 0.8999732136726379,
                "text_label": "positive",
                "date_published": "4 hours ago",
                "publisher": "Yahoo Finance Video"
            },
            {
                "headline": "Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report?",
                "headline_score": 0.9681519865989685,
                "headline_label": "negative",
                "article_text": "Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report?\nZacks Equity Research\nFri, Jun 7, 2024, 10:30 AM4 min read\nIn This Article:\nEXAS\n002722.SZ\nA month has gone by since the last earnings report for Exact Sciences (EXAS). Shares have lost about 17.5% in that time frame, underperforming the S&P 500.\nWill the recent negative trend continue leading up to its next earnings release, or is Exact Sciences due for a breakout? Before we dive into how investors and analysts have reacted as of late, let",
                "text_score": 0.9642665386199951,
                "text_label": "negative",
                "date_published": "8 hours ago",
                "publisher": "Zacks"
            },
            {
                "headline": "FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug",
                "headline_score": 0.774440586566925,
                "headline_label": "positive",
                "article_text": "FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug\nVandana Singh\nFri, Jun 7, 2024, 8:49 AM2 min read\nIn This Article:\nGERN\nBMY\n002722.SZ\nFDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug\nOn Thursday, the FDA approved Geron Corporation's (NASDAQ:GERN) Rytelo (imetelstat) for adult patients with low-to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia.\nThe approval covers patien",
                "text_score": 0.5603578686714172,
                "text_label": "neutral",
                "date_published": "10 hours ago",
                "publisher": "Benzinga"
            },
            {
                "headline": "Geron wins long-sought drug approval; Califf talks China, GLP-1s at BIO",
                "headline_score": 0.785423994064331,
                "headline_label": "positive",
                "article_text": "Geron wins long-sought drug approval; Califf talks China, GLP-1s at BIO\nBioPharma Dive\u00b7 Industry Dive\nBioPharma Dive staff\nFri, Jun 7, 2024, 7:30 AM3 min read\nIn This Article:\n002722.SZ\nABBV\nToday, several brief updates from BioPharma Dive Reporter Gwendolyn Wu, who spent this week attending BIO\u2019s annual meeting in San Diego, as well as notes on Geron, AbbVie and Deerfield Management.\nFood and Drug Administration Commissioner Robert Califf, speaking on a Wednesday panel, told BIO president John Crowley that",
                "text_score": 0.9179518818855286,
                "text_label": "neutral",
                "date_published": "12 hours ago",
                "publisher": "BioPharma Dive"
            },
            {
                "headline": "Midday movers: GameStop, DocuSign fall; Lyft, Geron rise",
                "headline_score": 0.7444667816162109,
                "headline_label": "neutral",
                "article_text": "Midday movers: GameStop, DocuSign fall; Lyft, Geron rise\nInvesting.com\nFri, Jun 7, 2024, 6:22 AM2 min read\nIn This Article:\nLYFT\nGME\n002722.SZ\nDOCU\nNVDA\n(Updated - June 7, 2024 11:18 AM EDT)\nInvesting.com -- U.S. stock futures were choppy Friday after data from the Labor Department showed stronger than expected job growth in May, reducing the likelihood the Fed will begin lowering interest rates in September.\nHere are some of the biggest U.S. stock movers today:\nGameStop (NYSE:GME) slumped 20% after the vid",
                "text_score": 0.9626451134681702,
                "text_label": "negative",
                "date_published": "13 hours ago",
                "publisher": "Investing.com"
            },
            {
                "headline": "FDA approves Geron\u2019s RYTELO for MDS associated anaemia",
                "headline_score": 0.538354754447937,
                "headline_label": "positive",
                "article_text": "FDA approves Geron\u2019s RYTELO for MDS associated anaemia\nPharmaceutical Technology\u00b7 LindseyRN / Shutterstock.\nGlobalData\nFri, Jun 7, 2024, 3:25 AM2 min read\nIn This Article:\n002722.SZ\nThe US Food and Drug Administration (FDA) has granted approval for Geron\u2019s RYTELO (imetelstat) for adults with low to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anaemia.\nThe approval marks a significant milestone for patients requiring red blood cell transfusions four or more times over eight ",
                "text_score": 0.920450747013092,
                "text_label": "positive",
                "date_published": "15 hours ago",
                "publisher": "Pharmaceutical Technology"
            },
            {
                "headline": "Geron Announces FDA Approval of RYTELO\u2122 (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia",
                "headline_score": 0.895337700843811,
                "headline_label": "positive",
                "article_text": "Geron Announces FDA Approval of RYTELO\u2122 (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia\nBusiness Wire\nThu, Jun 6, 2024, 8:58 PM13 min read\nIn This Article:\nGERN\nApproval across ESA ineligible and ESA relapsed/refractory patients with LR-MDS with transfusion-dependent anemia, regardless of ring sideroblast (RS) status\nDurable and sustained red blood cell transfusion independence, increases in hemoglobin levels and ",
                "text_score": 0.9037802219390869,
                "text_label": "positive",
                "date_published": "22 hours ago",
                "publisher": "Business Wire"
            }
        ]
    },
    {
        "No.": "7",
        "Ticker": "MAIA",
        "Company": "MAIA Biotechnology Inc",
        "Sector": "Healthcare",
        "Industry": "Biotechnology",
        "Country": "USA",
        "Market Cap": "86.60M",
        "Price": "3.96",
        "Change": "19.43%",
        "Volume": "1,185,021",
        "Sentiment Scores": [
            {
                "headline": "MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA\u2019s Approval of a Telomerase Inhibitor Agent Therapy",
                "headline_score": 0.8578794002532959,
                "headline_label": "positive",
                "article_text": "MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA\u2019s Approval of a Telomerase Inhibitor Agent Therapy\nBusiness Wire\nFri, Jun 7, 2024, 11:31 AM5 min read\nIn This Article:\nMAIA\nFDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment\nCHICAGO, June 07, 2024--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (\"MAIA\", the \"Company\"), a clinical-stage company developing telomere-targeting immunotherapies for cancer, today an",
                "text_score": 0.5493659973144531,
                "text_label": "neutral",
                "date_published": "7 hours ago",
                "publisher": "Business Wire"
            }
        ]
    },
    {
        "No.": "8",
        "Ticker": "TCJH",
        "Company": "Top KingWin Ltd",
        "Sector": "Financial",
        "Industry": "Capital Markets",
        "Country": "China",
        "Market Cap": "7.16M",
        "Price": "0.49",
        "Change": "18.32%",
        "Volume": "1,391,499",
        "Sentiment Scores": []
    },
    {
        "No.": "9",
        "Ticker": "ICU",
        "Company": "SeaStar Medical Holding Corp",
        "Sector": "Healthcare",
        "Industry": "Biotechnology",
        "Country": "USA",
        "Market Cap": "19.01M",
        "Price": "0.25",
        "Change": "17.48%",
        "Volume": "6,137,405",
        "Sentiment Scores": [
            {
                "headline": "Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical\u2019s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation",
                "headline_score": 0.9048854112625122,
                "headline_label": "neutral",
                "article_text": "Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical\u2019s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation\nSeaStar Medical Holding Corporation\nFri, Jun 7, 2024, 7:30 AM6 min read\nIn This Article:\nICU\nICUCW\nSeaStar Medical Holding Corporation\nDENVER, June 07, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflam",
                "text_score": 0.838316798210144,
                "text_label": "neutral",
                "date_published": "11 hours ago",
                "publisher": "GlobeNewswire"
            }
        ]
    },
    {
        "No.": "10",
        "Ticker": "HUDA",
        "Company": "Hudson Acquisition I Corp",
        "Sector": "Financial",
        "Industry": "Shell Companies",
        "Country": "USA",
        "Market Cap": "57.64M",
        "Price": "12.81",
        "Change": "16.98%",
        "Volume": "467,816",
        "Sentiment Scores": []
    },
    {
        "No.": "11",
        "Ticker": "JDST",
        "Company": "Direxion Daily Junior Gold Miners Index Bear -2X Shares",
        "Sector": "Financial",
        "Industry": "Exchange Traded Fund",
        "Country": "USA",
        "Market Cap": "-",
        "Price": "3.94",
        "Change": "15.35%",
        "Volume": "9,337,560",
        "Sentiment Scores": []
    }
]